Yang Jianmei, Sun Yan, Chen Chen
Department of Paediatric Endocrinology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
Endocrinology, SBMS, Faculty of Medicine, The University of Queensland, St Lucia, Australia.
Intractable Rare Dis Res. 2025 Aug 31;14(3):216-222. doi: 10.5582/irdr.2025.01043.
X-linked nephrogenic diabetes insipidus (X-NDI) is a rare congenital disease caused by inactivating mutations of the vasopressin type-2 receptor (), characterized by impaired renal concentrating ability, dramatic polyuria, polydipsia and risk of dehydration. This study aims to elucidate the pathogenic mechanisms associated with a novel variant in the gene, which has been implicated in X-NDI. Whole exome sequencing (WES) was employed to identify genetic variants, complemented by bioinformatic analyses to predict the functional impact of these mutations. A male patient, aged 11.5 years, presented with polydipsia, polyuria, rapid weight gain, and associated physical anomalies, alongside hormonal imbalances and elevated serum sodium and chloride levels. Notably, WES revealed a hemi variant in the gene (NM_000054.6:exon3:c.245G>A(p. Cys82Tyr)), classified as a variant of uncertain significance. The findings indicate that a combined pharmacological approach can effectively manage X-NDI symptoms without significant side effects, suggesting a favorable prognosis for the patient. After hydrochlorothiazide for one month, both serum sodium and chloride recovered a normal level. This study highlights the importance of early diagnosis and personalized treatment strategies in enhancing patient outcomes. Future research should focus on expanding genetic testing within the population to further elucidate the genetic underpinnings of X-NDI and explore the potential for targeted therapies, ultimately improving the management of this challenging condition. This newly identified mutation expands the spectrum of mutations in X-NDI.
X连锁肾性尿崩症(X-NDI)是一种罕见的先天性疾病,由血管加压素2型受体()的失活突变引起,其特征为肾浓缩能力受损、显著多尿、烦渴和脱水风险。本研究旨在阐明与该基因中一个新变异相关的致病机制,该变异与X-NDI有关。采用全外显子组测序(WES)来识别基因变异,并辅以生物信息学分析来预测这些突变的功能影响。一名11.5岁男性患者表现出烦渴、多尿、体重快速增加以及相关身体异常,同时伴有激素失衡以及血清钠和氯水平升高。值得注意的是,WES在该基因中发现了一个半合子变异(NM_000054.6:exon3:c.245G>A(p.Cys82Tyr)),分类为意义未明的变异。研究结果表明,联合药物治疗方法可有效控制X-NDI症状且无明显副作用,提示患者预后良好。服用氢氯噻嗪一个月后,血清钠和氯均恢复到正常水平。本研究强调了早期诊断和个性化治疗策略对改善患者预后的重要性。未来研究应聚焦于在人群中扩大基因检测,以进一步阐明X-NDI的遗传基础并探索靶向治疗的潜力,最终改善对这一具有挑战性疾病的管理。这个新发现的突变扩展了X-NDI的突变谱。